The selection of commercially viable drug candidates and advancing their development
toward worldwide markets is a complex and challenging task that requires people with a broad
range of different qualifications and drug development know-how.

Martin Emilio Munk

Preclinical drug development specialist

Back to team

Martin studied medicine at the University of Rio de Janeiro and Immunology and Microbiology at São Paulo Medical University. He earned an MD from the Department of Immunology, University of Ulm, Germany. After a completing a post-doctoral fellowship at the Max-Plank Institute for Immunobiology, Germany, Martin served in various academic research positions, including Assistant Professor, Immunology, University of Ulm; University Assistant Researcher, Rheumatology and Clinical Immunology, Charité University Hospital, Humboldt University, Germany; Senior Scientist, Immunology, Max-Planck-Institute for Infection Biology, Germany; and Invited Professor and Senior Scientist, Tuberculosis Immunology, Statens Serum Institute, Denmark. In 2002, he served as Principal Scientist in the department of Preclinical Safety at Genmab A/S, Copenhagen. In 2007, Martin became Director, Preclinical Safety and Bioassay, of the Department of Product Development at Santaris Pharma A/S, Denmark. He later served at Novo Nordisk A/S, Denmark, as Global Medical Advisor (Principal Scientist), GLP-1 Medical Affairs and Modern Insulin & Devices.